Furukawa and colleagues have recently demonstrated that, among patients with PTLD and EBV-positive lymphoma, the PI3K/Akt/mTOR pathway is constitutively active, and that the combination of SRL with PI3K delta inhibitor synergistically suppresses the proliferation of EBV-positive B lymphoma cells [12]. The gene discussed is SRL; the disease is post-transplant lymphoproliferative disease.